Association between Serum Biomarker Profile and Real-World Evidence of Disability in Multiple Sclerosis

被引：0
|
作者：
Zhu, W. [1 ]
Chen, C. [1 ]
Zhang, L. [1 ]
Hoyt, T. [2 ]
Walker, E. [1 ]
Venkatesh, S. [1 ]
Zhang, F. [3 ]
Qureshi, F. [3 ]
Foley, J. [2 ]
Xia, Z. [1 ]
机构：
[1] Univ Pittsburgh, Neurol, Pittsburgh, PA USA
[2] Rocky Mt Multiple Sclerosis Clin, Salt Lake City, UT USA
[3] Octave Biosci Inc, Assay Dev, Menlo Pk, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P006
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [31] Real-world study: from real-world data to real-world evidence
    Wen, Yi
    TRANSLATIONAL BREAST CANCER RESEARCH, 2020, 1
  • [32] Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study
    Silva, Berenice
    Casales, Federico
    Donoso, Claudia Burbano
    Varela, Lucia
    Heriz, Alejandra
    Gonzalez, Cecilia
    Miguez, Jimena
    Alonso, Ricardo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 90
  • [33] Effectiveness and safety of dimethyl fumarate treatment in relapsing multiple sclerosis patients: Real-world evidence
    Alroughani R.
    Ahmed S.F.
    Behbehani R.
    Al-Hashel J.
    Neurology and Therapy, 2017, 6 (2) : 189 - 196
  • [34] Effectiveness and safety of dimethyl fumarate treatment in patients with relapsing multiple sclerosis: A real-world evidence
    Alroughani, Raed
    Ahmed, Samar
    Behbehani, Raed
    Al-hashel, Jasem
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP17 - NP17
  • [35] Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis
    Ness, Nils-Henning
    Schriefer, Dirk
    Haase, Rocco
    Ettle, Benjamin
    Ziemssen, Tjalf
    PHARMACOECONOMICS, 2020, 38 (08) : 883 - 892
  • [36] Serum neurofilaments as a potential biomarker of disability and cognitive decline in patients with multiple sclerosis
    Yanakieva, Magdalina
    Ovcharova, Emilia
    Danovska, Maya
    Marinova-Trifonova, Diana
    Atanasova, Milena
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 980 - 981
  • [37] Natalizumab Treatment Outcomes and Safety Profile in Women with Multiple Sclerosis: Insights from Real-world Data
    Simsek, Yasemin
    Abasiyanik, Zuhal
    Samadzade, Ulvi
    Ozakbas, Serkan
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 806 - 806
  • [38] Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
    Sempere, Angel P.
    Berenguer-Ruiz, Leticia
    Borrego-Soriano, Ines
    Burgos-San Jose, Amparo
    Concepcion-Aramendia, Luis
    Volar, Lucian
    Aragones, Miguel
    Palazon-Bru, Antonio
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [39] Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review
    Montalban, Xavier
    Matthews, Paul M.
    Simpson, Alex
    Petrie, John L.
    Sammon, Cormac
    Ramagopalan, Sreeram
    Disanto, Giulio
    Kuhle, Jens
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2023, 10 (03): : 302 - 311
  • [40] Real-world experience of ofatumumab in Chinese multiple sclerosis patients
    Tan, Hongmei
    ZhangBao, Jingzi
    Zhou, Lei
    Zhao, Chongbo
    Quan, Chao
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1112 - 1113
12345